[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247636":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":23,"id":57,"slug":23,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":23,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":23,"overallStatus":39,"whyStopped":23,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LDN","EXPERIMENTAL","Naltrexone HCL, 4.5 mg, Once a day.",[13],"Drug: LDN",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Sugar pill",[19],"Drug: Placebo",[21,25],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":23},"DRUG",null,[9],{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":23},[15],[28],{"name":29,"affiliation":5,"role":30},"Sean Mackey, MD, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Birute Gedrimaite","CONTACT","(650) 497-0485","birute@stanford.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Palo Alto","California","94304","United States",{"type":45,"coordinates":46},"Point",[47,48],-122.14302,37.44188,{"lat":48,"lon":47},[51,53],{"name":33,"role":34,"phone":52,"phoneExt":23,"email":36},"650-497-0485",{"name":29,"role":30,"phone":23,"phoneExt":23,"email":23},{"type":30,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Sean Mackey","Redlich Professor Departments of Anesthesiology, Perioperative and Pain Medicine | Neurosciences | Neurology (by courtesy), Chief, Division of Pain Medicine, Director, Stanford Systems Neuroscience and Pain Lab (SNAPL), Stanford University","100247636",false,"NCT02502162","Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome","LDN-CRPS","Inclusion Criteria:\n\n* Upper and\u002For lower extremity CRPS\n* On stable treatment for 1 month\n* CRPS for at least 1 year\n* Meet the Budapest criteria for CRPS at time of the study.\n\nExclusion Criteria:\n\n* Any known allergy to naltrexone or naloxone\n* Use of prescription opioid analgesics or illegal opioid use\n* Current or planned pregnancy.","ALL","18 Years","70 Years",{"count":67,"type":68},120,"ESTIMATED","INTERVENTIONAL",[71],"NA","The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.",[74],"Complex Regional Pain Syndrome","2025-05-27",{"date":77,"type":78},"2025-05-29","ACTUAL",{"date":80,"type":23},"2015-06",{"date":82,"type":68},"2027-07",{"name":5,"class":6},1]